Bebifrin Nazal drop. 0.125% 10 ml vial Cap

Description

Composition
Active substance:
1 ml contains: 1.25 mg phenylephrine hydrochloride.
Excipients:
0.18 mg Benzalkonium chloride, glycerol, anhydrous 50.00 mg macrogol 1500 (polyethylene glycol 1500) 15.00 mg Sodium hydrogen phosphate dihydrate 2.26 mg, 1.01 mg Potassium dihydrogen phosphate, disodium edetate dihydrate (Trilon B) 0.20 mg water for injections to 1 mL.
Description:
Transparent colorless or weakly colored liquid.
Product form:
Nasal drops of 0.125%.
10 or 15 ml in a vial, plastic and plastic with a dropper cap with tamper-evident vial or dropper-polymer together with the lid and screwed plug-dropper.
1 bottle together with instructions for use in a stack of cardboard.
Contraindications
Increased individual sensitivity to the drug; diseases of the cardiovascular system (including koronaroskleroza, angina), hypertensive crisis, hyperthyroidism, diabetes mellitus, concomitant use of monoamine oxidase inhibitors (MAOIs) (as well as 2 weeks after their cancellation).
Carefully
Children up to age 6 years.
Dosage
1.25 mg / ml
Indications
Symptomatic treatment to facilitate breathing through the nose for colds, flu, hay fever and other allergic diseases of the upper respiratory tract involving acute rhinitis or sinusitis.
Interaction with other drugs
MAO inhibitors (procarbazine, selegine), tricyclic antidepressants, maprotiline, guanedrel, guanethidine pressor effect and enhance arrhythmogenic phenylephrine (for systemic absorption). Thyroid hormones increase (each with systemic absorption of phenylephrine) the associated risk of coronary heart disease (particularly in coronary atherosclerosis).
Overdose
Data on overdose of the drug available. Potentially possible symptoms (for systemic absorption): ventricular premature beats, short paroxysms of ventricular tachycardia, feeling of heaviness in the head and legs, the excessive increase in blood pressure, agitation.
Treatment: intravenous alpha-blockers short-acting (phentolamine) and beta-blockers (for rate violations).
pharmachologic effect
Pharmacological group:
Decongestant agent – alpha-agonists.
Pharmacodynamics:
Phenylephrine hydrochloride is for providing vasoconstrictive action due to stimulation of alpha 1 receptors in the nasal mucosa, reduces the swelling of mucous membranes and hyperemia of tissues, congestion in the nasal mucosa, and enhances the permeability of the nasal airway agonist alpha1-adrenergic receptors (a sympathomimetic).
Pharmacokinetics:
When applied topically, low systemic absorption.
Pregnancy and breast-feeding
Sufficient experience of use of the drug during pregnancy is not. It can be used for the treatment of pregnant women and nursing mothers prescribed by a doctor, if the potential benefit to the mother outweighs the potential risk to the fetus or child.
Conditions of supply of pharmacies
Without a prescription.
side effects
Local reactions: sometimes burning, tingling or tingling in the nose.
Systemic effects: headache, dizziness, palpitations, arrhythmia, increased blood pressure, sweating, pallor, tremor, insomnia.
If any of these instructions side effects are compounded or you notice any other side effects not mentioned in the instructions, tell your doctor.
special instructions
Children from 0 to 1 year of use strictly on doctor’s prescription and no more frequently than every 6 hours. Children systemic absorption of phenylephrine and the associated risk of side effects is higher than in adults. Phenylephrine should not be administered to patients within 2 weeks after discontinuation of MAO inhibitors, because they can increase the severity of adrenergic sympathomimetic effects and increase the risk of side effects of the cardiovascular system. The duration of the drug should not exceed 3 days, while maintaining hindered nasal breathing for further use of the drug should consult a physician. To prevent the spread of infection it is necessary to use the drug individually.
The effect on the ability of control of vehicles and mechanisms
No Information about the negative impact of the drug on the ability to drive a car and other vehicles. However, if symptoms persist side effects of the drug should refrain from driving and perform actions that require concentration and psychomotor speed reactions.
Storage conditions
Store at a temperature not higher than 25 ° C.
Keep out of the reach of children.
Dosing and Administration
Intranasally.
For children aged 0 to 1 year: single dose – 1 drop of no more frequently than every 6 hours.
For children aged 1 to 6 years: single dose – 1-2 drops.
For children older than 6 years and adults: a single dose – 3-4 drops.
After use should be wiped dry dropper.
Duration of treatment – no more than 3 days.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist